Ines Dufait
Ines Dufait
LMCT/TROP at the VUB
Dirección de correo verificada de vub.ac.be
Título
Citado por
Citado por
Año
Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy
T Liechtenstein, I Dufait, A Lanna, K Breckpot, D Escors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly …, 2012
442012
PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal
T Liechtenstein, I Dufait, C Bricogne, A Lanna, J Pen, K Breckpot, ...
Journal of clinical & cellular immunology, 2012
412012
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer
I Dufait, JK Schwarze, T Liechtenstein, W Leonard, H Jiang, D Escors, ...
Oncotarget 6 (14), 12369, 2015
402015
Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species
H Wang, S Bouzakoura, S De Mey, H Jiang, K Law, I Dufait, C Corbet, ...
Oncotarget 8 (22), 35728, 2017
322017
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
D Escors, T Liechtenstein, N Perez-Janices, J Schwarze, I Dufait, ...
Oncoimmunology 2 (10), e26148, 2013
312013
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of …
T Liechtenstein, N Perez-Janices, I Blanco-Luquin, C Goyvaerts, ...
Oncoimmunology 3 (7), e945378, 2014
302014
Immune modulation by genetic modification of dendritic cells with lentiviral vectors
T Liechtenstein, N Perez-Janices, C Bricogne, A Lanna, I Dufait, ...
Virus research 176 (1-2), 1-15, 2013
252013
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
I Dufait, E Van Valckenborgh, E Menu, D Escors, M De Ridder, K Breckpot
Oncotarget 7 (27), 42698, 2016
202016
Retroviral and lentiviral vectors for the induction of immunological tolerance
I Dufait, T Liechtenstein, A Lanna, C Bricogne, R Laranga, A Padella, ...
Scientifica 2012, 2012
182012
Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion
W Leonard, I Dufait, JK Schwarze, K Law, B Engels, H Jiang, ...
Radiotherapy and Oncology 119 (2), 291-299, 2016
142016
Antidiabetic Biguanides Radiosensitize Hypoxic Colorectal Cancer Cells Through a Decrease in Oxygen Consumption
S de Mey, H Jiang, C Corbet, H Wang, I Dufait, K Law, E Bastien, ...
Frontiers in pharmacology 9, 1073, 2018
52018
Lentiviral Vectors in Immunotherapy
I Dufait, T Liechtenstein, A Lanna, R Laranga, A Padella, C Bricogne, ...
Gene Therapy-Tools and Potential Applications, 2013
42013
Critical mass hypothesis of T-cell responses and its application for the treatment of T-cell lymphoma
C Bricogne, R Laranga, A Padella, I Dufait, T Liechtenstein, K Breckpot, ...
Hodgkin’s and T-cell lymphoma: Diagnosis, Treatment Options and Prognosis …, 2012
42012
Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment?
R Suzuki, R Komaki
Radiotherapy and Oncology 127 (3), 339-343, 2018
32018
Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer
S de Mey, H Jiang, H Wang, B Engels, T Gevaert, I Dufait, O Feron, J Aerts, ...
Radiotherapy and Oncology 127 (3), 361-369, 2018
22018
Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy
T Liechtenstein, N Perez-Janices, K Breckpot, D Escors
Human Gene Therapy 24 (12), A166-A166, 2013
22013
SCIDOT-30. GLITIPNI: A PHASE 1B CLINICAL TRIAL COMBINING SURGICAL RESECTION WITH DIRECT INTRACEREBRAL INJECTION OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RECURRENT …
J Duerinck, G Awada, J Katharina Schwarze, I Dufait, S Peeters, ...
Neuro-Oncology 21 (Supplement_6), vi277-vi278, 2019
12019
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
JK Schwarze, J Duerinck, I Dufait, G Awada, S Klein, L Fischbuch, ...
Journal of Clinical Oncology 38 (15_suppl), 2534-2534, 2020
2020
A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced …
JK Schwarze, G Awada, L Cras, I Dufait, R Forsyth, I Van Riet, B Neyns
JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019
2019
Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells
I Dufait, J Pardo, D Escors, Y De Vlaeminck, H Jiang, M Keyaerts, ...
Cancers 11 (6), 808, 2019
2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20